ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arbutus Biopharma Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.23+0.01 (+0.24%)
Close on Oct 19, 2026
- Market cap
- $835.30M
- P/E (TTM)
- 5.4
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
71.1%
141M of 198M shares
Institutional holders
177
34 new, 22 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roivant Sciences Ltd. | 29,880,079 | 19.50% | 13D (active) amendment | Oct 1, 2026 |
| Morgan Stanley | 18,682,708 | 12.20% | 13G (passive) amendment | Sep 30, 2026 |
| Two Seas Capital LP | 18,557,543 | 9.40% | 13G (passive) amendment | Mar 31, 2026 |
| Whitefort Capital Master Fund, LP | 15,794,261 | 8.10% | 13D (active) amendment | Apr 10, 2026 |
| Joseph Kaplan | 15,794,261 | 8.00% | 13G (passive) | Sep 4, 2026 |
| Whitefort Capital Management, LP | 15,794,261 | 8.00% | 13D (active) amendment | Apr 24, 2026 |
| David Salanic | 13,307,967 | 7.00% | 13D (active) amendment | Feb 20, 2025 |
| Two Seas Capital GP LLC | 12,589,158 | 6.50% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 10,390,300 | 6.20% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ABUS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Two Seas Capital LP | 19,095,583 | 9.65% | $91.66M | +538,040 | 1.82% |
| Morgan Stanley | 17,698,305 | 8.95% | $84.95M | −8,193,175 | 0.00% |
| Whitefort Capital Management, LP | 15,794,261 | 7.98% | $75.81M | +863,376 | 18.69% |
| BlackRock, Inc. | 13,766,071 | 6.96% | $66.08M | +799,125 | 0.00% |
| State Street Corp | 7,869,179 | 3.98% | $37.77M | +1,526,669 | 0.00% |
| Rubric Capital Management LP | 7,532,937 | 3.81% | $36.16M | +906,548 | 0.33% |
| Vanguard Capital Management LLC | 7,010,679 | 3.54% | $33.65M | +321,768 | 0.00% |
| Barclays PLC | 4,207,914 | 2.13% | $20.20M | −108,181 | 0.00% |
| Geode Capital Management, LLC | 4,117,691 | 2.08% | $19.77M | +345,885 | 0.00% |
| Goldman Sachs Group Inc | 3,506,802 | 1.77% | $16.83M | +2,406,368 | 0.00% |
| Bank Of America Corp /De/ | 2,646,197 | 1.34% | $12.70M | +962,569 | 0.00% |
| BlackBarn Capital Partners LP | 2,500,000 | 1.26% | $12.00M | – | 1.01% |
| Legal & General Group Plc | 2,466,127 | 1.25% | $11.84M | +64,738 | 0.00% |
| Woodline Partners LP | 2,281,856 | 1.15% | $10.95M | +271,684 | 0.03% |
| Jefferies Financial Group Inc. | 1,711,672 | 0.87% | $8.22M | −182,395 | 0.05% |
| Nomura Holdings Inc | 1,637,081 | 0.83% | $7.86M | New | 0.01% |
| Vanguard Portfolio Management LLC | 1,541,458 | 0.78% | $7.40M | +149,434 | 0.00% |
| Charles Schwab Investment Management Inc | 1,431,218 | 0.72% | $6.87M | +30,061 | 0.00% |
| Northern Trust Corp | 1,419,024 | 0.72% | $6.81M | +141,165 | 0.00% |
| Osaic Holdings, Inc. | 1,347,866 | 0.68% | $6.47M | −261 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 177 | 141M | 71.1% | 34 / 63 | 41 / 22 | 18M | 16M |
| Q1 2026 | 167 | 139M | 70.3% | 29 / 48 | 48 / 31 | 36M | 9M |
| Q4 2025 | 172 | 122M | 61.7% | 22 / 55 | 45 / 15 | 13M | 9M |
| Q3 2025 | 166 | 118M | 59.8% | 21 / 51 | 54 / 16 | 7M | 7M |
| Q2 2025 | 162 | 118M | 59.8% | 14 / 64 | 45 / 18 | 10M | 3M |
| Q1 2025 | 167 | 112M | 56.5% | 26 / 46 | 52 / 9 | 11M | 3M |
| Q4 2024 | 153 | 104M | 52.6% | 22 / 56 | 41 / 13 | 8M | 5M |
| Q3 2024 | 144 | 101M | 51.1% | 29 / 46 | 32 / 12 | 21M | 5M |
| Q2 2024 | 131 | 97M | 48.9% | 23 / 48 | 31 / 10 | 10M | 15M |
| Q1 2024 | 119 | 101M | 51.1% | 20 / 32 | 35 / 13 | 23M | 8M |
| Q4 2023 | 112 | 86M | 43.5% | 21 / 35 | 28 / 7 | 17M | 6M |
| Q3 2023 | 99 | 75M | 37.9% | 5 / 36 | 23 / 16 | 14M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ABUS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5,034,547 | 2.54% | $24.17M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,110,249 | 2.08% | $19.73M | 0.02% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,675,728 | 1.86% | $17.64M | 0.16% | Jun 30, 2026 |
| Morgan Stanley Insight Fund | 2,728,775 | 1.38% | $13.10M | 1.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,795,131 | 0.91% | $8.62M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,759,046 | 0.89% | $7.63M | 0.02% | Jul 31, 2026 |
| Inception Portfolio | 1,626,723 | 0.82% | $7.81M | 2.77% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,477,677 | 0.75% | $7.09M | 0.05% | Jun 30, 2026 |
| EQ/Morgan Stanley Small Cap Growth Portfolio | 1,299,763 | 0.66% | $6.24M | 1.31% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,107,700 | 0.56% | $5.32M | 0.06% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 794,940 | 0.40% | $3.62M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 778,182 | 0.39% | $3.55M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 734,401 | 0.37% | $3.35M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 539,841 | 0.27% | $2.59M | 0.17% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF | 537,087 | 0.27% | $2.58M | 0.09% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lindsay Androski | President and CEO, Director | 154,864 | 0.08% | Sep 23, 2026 |
| Michael J. McElhaugh | Interim President & CEO, Director | 1,658,003 | 0.84% | Feb 19, 2025 |
| Tuan Nguyen | Chief Financial Officer | 366,600 | 0.19% | Sep 23, 2026 |
| David C. Hastings | Chief Financial Officer | 249,824 | 0.13% | Feb 19, 2025 |
| Karen Sims | Chief Medical Officer | 155,494 | 0.08% | Feb 19, 2025 |
| J. Christopher Naftzger | General Counsel and CCO | 140,544 | 0.07% | Feb 19, 2025 |
| Robert A. Beardsley | Director | 131,333 | 0.07% | Sep 23, 2026 |
| Roger Sawhney | Director | 52,533 | 0.03% | Sep 23, 2026 |
| Anuj Hasija | Director | – | – | Mar 20, 2025 |
| Joseph E. Bishop | Director | – | – | Mar 6, 2025 |
| Matthew Gline | Director, 10% owner | 38,847,462 | 19.64% | Mar 6, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Roger Sawhney Director | Sep 18, 2026 | Option exercise | +52,533 | $3.34 | $175.46K | 52,533 |
| Roger Sawhney Director | Sep 18, 2026 | Option exercise | +78,800 | $4.24 | $334.11K | 131,333 |
| Roger Sawhney Director | Sep 18, 2026 | Tax withholding | −100,508 | $5.07 | $509.58K | 30,825 |
| Tuan Nguyen Chief Financial Officer | Sep 18, 2026 | Option exercise | +27,475 | $4.39 | $120.62K | 366,600 |
| Tuan Nguyen Chief Financial Officer | Sep 18, 2026 | Tax withholding | −206,637 | $5.07 | $1.05M | 159,963 |
| Tuan Nguyen Chief Financial Officer | Sep 18, 2026 | Option exercise | +265,625 | $3.49 | $927.03K | 339,125 |
| Robert A. Beardsley Director | Sep 18, 2026 | Option exercise | +78,800 | $4.24 | $334.11K | 131,333 |
| Robert A. Beardsley Director | Sep 18, 2026 | Option exercise | +52,533 | $3.20 | $168.11K | 52,533 |
| Robert A. Beardsley Director | Sep 18, 2026 | Tax withholding | −99,057 | $5.07 | $502.22K | 32,276 |
| Lindsay Androski President and CEO, Director | Sep 18, 2026 | Option exercise | +10,456 | $4.39 | $45.90K | 154,864 |
| Lindsay Androski President and CEO, Director | Sep 18, 2026 | Tax withholding | −82,527 | $5.07 | $418.41K | 72,337 |
| Lindsay Androski President and CEO, Director | Sep 18, 2026 | Option exercise | +116,408 | $3.20 | $372.51K | 144,408 |
| Lindsay Androski President and CEO, Director | Feb 2, 2026 | Award | +28,000 | – | – | 28,000 |
| Tuan Nguyen Chief Financial Officer | Feb 2, 2026 | Award | +73,500 | – | – | 73,500 |
| David C. Hastings Chief Financial Officer | Feb 14, 2025 | Award | +90,100 | – | – | 249,824 |
| Karen Sims Chief Medical Officer | Feb 14, 2025 | Award | +49,300 | – | – | 155,494 |
| J. Christopher Naftzger General Counsel and CCO | Feb 14, 2025 | Award | +54,300 | – | – | 140,544 |
| Michael J. McElhaugh Interim President & CEO, Director | Feb 14, 2025 | Award | +177,000 | – | – | 1,658,003 |
| David C. Hastings Chief Financial Officer | Feb 4, 2025 | Sale(10b5-1 plan) | −22,183 | $3.28 | $72.76K | 159,724 |
| Michael J. McElhaugh Interim President & CEO, Director | Feb 4, 2025 | Sale(10b5-1 plan) | −23,790 | $3.28 | $78.03K | 1,481,003 |
| Karen Sims Chief Medical Officer | Feb 4, 2025 | Sale(10b5-1 plan) | −19,348 | $3.28 | $63.46K | 106,194 |
| J. Christopher Naftzger General Counsel and CCO | Feb 4, 2025 | Sale(10b5-1 plan) | −11,333 | $3.28 | $37.17K | 86,244 |
| Keith S. Manchester Director | Aug 14, 2024 | Option exercise | +54,915 | $0.56 | $30.75K | 54,915 |
| Keith S. Manchester Director | Aug 14, 2024 | Sale | −8,846 | $3.69 | $32.64K | 46,069 |
| Michael J. Sofia Chief Scientific Officer | Feb 2, 2024 | Sale(10b5-1 plan) | −9,982 | $2.31 | $23.06K | 1,485,121 |
| David C. Hastings Chief Financial Officer | Feb 2, 2024 | Sale(10b5-1 plan) | −9,593 | $2.31 | $22.16K | 181,907 |
| Michael J. McElhaugh Interim President & CEO, Director | Feb 2, 2024 | Sale(10b5-1 plan) | −10,164 | $2.31 | $23.48K | 1,504,793 |
| Karen Sims Chief Medical Officer | Feb 2, 2024 | Sale(10b5-1 plan) | −4,358 | $2.31 | $10.07K | 125,542 |
| J. Christopher Naftzger General Counsel and CCO | Feb 1, 2024 | Award | +95,100 | – | – | 95,100 |
| Michael J. Sofia Chief Scientific Officer | Feb 1, 2024 | Award | +109,500 | – | – | 1,495,103 |
| David C. Hastings Chief Financial Officer | Feb 1, 2024 | Award | +112,500 | – | – | 191,500 |
| Michael J. McElhaugh Interim President & CEO, Director | Feb 1, 2024 | Award | +123,800 | – | – | 1,514,957 |
| Karen Sims Chief Medical Officer | Feb 1, 2024 | Award | +101,000 | – | – | 129,900 |
| Michael J. Sofia Chief Scientific Officer | Feb 1, 2023 | Award | +82,200 | – | – | 1,385,603 |
| Elizabeth Howard EVP, GC, Compliance | Feb 1, 2023 | Award | +69,700 | – | – | 86,024 |
| Michael J. McElhaugh Chief Business Officer | Feb 1, 2023 | Award | +83,700 | – | – | 1,391,157 |
| William H. Collier President and CEO, Director | Feb 1, 2023 | Award | +216,500 | – | – | 216,500 |
| David C. Hastings Chief Financial Officer | Feb 1, 2023 | Award | +79,000 | – | – | 79,000 |
| Michael J. Sofia Chief Scientific Officer | Dec 1, 2021 | Sale(10b5-1 plan) | −200,000 | $5.09 | $1.02M | 1,303,403 |
| Sciences Ltd. Roivant 10% owner | Oct 18, 2021 | Conversion | +22,833,922 | – | – | 38,847,462 |
| Michael J. McElhaugh Chief Business Officer | Feb 9, 2021 | Sale(10b5-1 plan) | −20,000 | $5.00 | $100.00K | 1,307,457 |
| Michael J. McElhaugh Chief Business Officer | Dec 14, 2020 | Sale(10b5-1 plan) | −30,000 | $5.00 | $150.00K | 1,337,457 |
| Michael J. McElhaugh Chief Business Officer | Dec 14, 2020 | Sale(10b5-1 plan) | −10,000 | $5.00 | $50.00K | 1,327,457 |
| Michael J. McElhaugh Chief Business Officer | Jul 23, 2020 | Sale(10b5-1 plan) | −20,000 | $5.01 | $100.20K | 1,367,457 |
| Mark J. Murray Director | Nov 28, 2018 | Option exercise | +25,000 | $1.35 | $33.75K | 341,396 |
| Michael J. Sofia Chief Scientific Officer | Aug 13, 2018 | Sale | −4,250 | $9.51 | $40.42K | 167,162 |
| Michael J. Sofia Chief Scientific Officer | Aug 13, 2018 | Sale | −4,250 | $9.51 | $40.42K | 1,499,153 |
| Michael J. Sofia Chief Scientific Officer | Jul 11, 2018 | Sale(10b5-1 plan) | −10,000 | $10.00 | $100.00K | 1,503,403 |
| Michael J. Sofia Chief Scientific Officer | Jul 9, 2018 | Sale(10b5-1 plan) | −10,000 | $8.91 | $89.10K | 1,513,403 |
| Michael J. Sofia Chief Scientific Officer | Jul 6, 2018 | Sale(10b5-1 plan) | −10,000 | $8.45 | $84.50K | 1,523,403 |
| Michael J. Sofia Chief Scientific Officer | Jul 5, 2018 | Sale(10b5-1 plan) | −10,000 | $8.40 | $84.00K | 1,533,403 |
| Michael J. Sofia Chief Scientific Officer | Jul 3, 2018 | Sale(10b5-1 plan) | −10,000 | $8.00 | $80.00K | 1,543,403 |
| Mark J. Murray President & CEO, Director | Apr 17, 2018 | Option exercise | +27,007 | $0.35 | $9.45K | 316,396 |
| Michael J. Sofia Chief Scientific Officer | Oct 3, 2017 | Sale(10b5-1 plan) | −10,000 | $8.00 | $80.00K | 1,553,403 |
| Michael J. Sofia Chief Scientific Officer | Aug 15, 2017 | Sale | −10,000 | $3.75 | $37.50K | 191,412 |
| Michael J. Sofia Chief Scientific Officer | Aug 15, 2017 | Sale | −20,000 | $3.68 | $73.60K | 171,412 |
| Michael J. Abrams Managing Director | Aug 16, 2016 | Option exercise | +14,178 | $0.35 | $4.96K | 42,097 |
| Mark J. Murray President & CEO, Director | Jun 16, 2016 | Option exercise | +5,000 | $2.57 | $12.85K | 289,389 |
| Michael J. Abrams Managing Director | Sep 11, 2015 | Option exercise | +17,044 | $0.44 | $7.50K | 27,919 |
| Mark J. Murray President & CEO | Sep 11, 2015 | Option exercise | +219,428 | $0.44 | $96.55K | 284,389 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michael J. McElhaugh Director | Apr 21, 2025 | 246,886 | $804.85K | Apr 21, 2025 | Stock Award |
| Michael J. McElhaugh Director | Apr 15, 2025 | 53,114 | $170.10K | Apr 15, 2025 | Stock Award |
| Michael J. Sofia Officer | Mar 31, 2025 | 250,000 | $875.00K | Mar 31, 2025 | Merger Acquisition |
| Michael J. Sofia Officer | Mar 24, 2025 | 250,000 | $820.00K | Mar 24, 2025 | Merger Acquisition |
| Michael J. Sofia Officer | Mar 19, 2025 | 150,000 | $480.00K | Mar 19, 2025 | Merger Acquisition |
| Michael J. Sofia Officer | Mar 13, 2025 | 100,000 | $338.00K | Mar 13, 2025 | Merger Acquisition |
| Michael J. Sofia Member of immediate family of any of the foregoing | Mar 7, 2025 | 167,162 | $549.96K | Mar 7, 2025 | Gift |
| C. Hastings David Officer | Feb 4, 2025 | 22,183 | $72.83K | Feb 4, 2025 | Restricted Stock Unit Vesting |
| Christopher Naftzger J. Officer | Feb 4, 2025 | 11,333 | $37.21K | Feb 4, 2025 | Restricted Stock Unit Vesting |
| Sims Karen Officer | Feb 4, 2025 | 19,348 | $63.52K | Feb 4, 2025 | Restricted Stock Unit Vesting |
| J. McElhaugh Michael Director and Officer | Feb 4, 2025 | 23,790 | $78.10K | Feb 4, 2025 | Restricted Stock Unit Vesting |